TVS Motor Company Creates a ‘New Freestyle Performance’ Segment with the Global Launch of Its All New Naked Sports TVS Apache RTR 310
Backed by a rich racing pedigree spanning over four decades, TVS Motor Company unveils the latest addition and a new flagship to its iconic Apache line-up: the TVS Apache RTR 310. This highly anticipated naked sports motorcycle is set to redefine the realm of two-wheeled exhilaration with its impressive blend of power, agility and style and is poised to captivate motorcycle enthusiasts and adrenaline aficionados around the world. It promises an unmatched riding experience, setting new benchmarks and offering a gateway into the world of the freestyler.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230906303314/en/
Vimal Sumbly, Head Business - Premium, TVS Motor Company and Dr Bernhard Heiming, CTO, TVS Motor Company (Photo: Business Wire)
The TVS Apache RTR 310 leads in innovation right from its unique design, engine layout, heat management and many differentiated technologies which are focused on rider engagement, safety and comfort.
Speaking on the occasion, Mr. Sudarshan Venu, Managing Director, TVS Motor Company, said, "TVS Motor Company has always transformed and redefined technology with the TVS Apache series at the helm, where we brought to life tech led innovations such as ride modes, slipper clutch, connectivity, fully adjustable suspension and the Built to Order Platform. The global launch of the all the new TVS Apache RTR 310 marks a momentous occasion for us, as this motorcycle encapsulates Apache’s 18 year legacy of innovation and performance. With the TVS Apache RTR 310, we're taking our engineering to a whole new level, offering enthusiasts a motorcycle that's not only powerful but also brings together different technologies to give a unique riding experience. This motorcycle is positioned to be the flagship product for many global markets including India, Europe, LATAM and ASEAN."
Speaking at the launch, Vimal Sumbly, Head Business – Premium, TVS Motor Company, said, “The TVS Apache RTR 310 is the first of a new generation of Apache’s that inherit a 40 year racing pedigree and are based on our ‘Track to Road’ philosophy. This machine will be the start of a new era of Freestyle Performance Motorcycling with a core essence of thrill and fun. With many defining technologies, this flagship Apache like every other Apache will lead in technology setting new benchmarks for the category. Its cyborg inspired streetfighter design, all range torque and track tuned agility, elevates the fun of motorcycling for the new age riders – Power to Play for the Freestyler.
The TVS Apache RTR series is already established as a formidable force in the naked format amongst premium lifestyle segment, The TVS Apache series recently crossed its 5 million global sales milestone becoming the fastest growing premium motorcycle brand in the segment.”
Redefining Tech:
|
Segment First |
Segment Defining |
|
|
■ Cruise Control |
■ Bidirectional Quickshifter |
|
|
■ Dynamic Class D LED Headlamp |
■ Race Tuned Linear Stability Control |
|
|
■ Dynamic Brake Lamp |
■ Lightweight aluminum sub frame |
|
|
■ 5 Ride Modes including all new Supermoto Mode |
■ Tire Pressure Monitoring System |
|
|
■ Climatic Control Seats (Heating and Cooling) |
■ Unique Reverse Inclined DOHC Engine |
|
|
■ 5” TFT Cluster with GoPro Control, Music Control, Voice Assist, Smart Helmet Device Connectivity, Telephony and Navigation |
|
|
|
■ Race Tuned Dynamic Stability Control with 6D IMU
|
|
|
Variant |
Price (Ex-Showroom India) |
|
Arsenal Black (w/o Quickshifter) |
₹ 2,42,990 |
|
Arsenal Black |
₹ 2,57,990 |
|
Fury Yellow |
₹ 2,63,990 |
|
BTO (Built To Order) |
|
|
•Dynamic Kit |
₹ 18,000 |
|
•Dynamic Pro Kit |
₹ 22,000 |
|
•Sepang Blue |
₹ 10,000 |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230906303314/en/
Contact information
Nikita Verma – nikita.verma@tvsmotor.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom